Dilution of Share Value from the Exercise of Stock Acquisition Rights
First written in FY2017. 4 of 8 entries say "Mitigated", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
53 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Series 11 stock acquisition rights: 152,800 shares at the end of the previous consolidated fiscal year; 16,400 shares forfeited; 136,400 shares remaining unconfirmed」
Of the Series 11 stock acquisition rights for employees, rights representing 16,400 shares expired due to employee departures, reducing the unconfirmed balance from 152,800 shares to 136,400 shares. Meanwhile, potential shares represented by the Series 9 and Series 10 stock acquisition rights remain outstanding. - FY2025-H1RestatedAnnual report
「Stock acquisition rights issued under the Companies Act during the interim accounting period were as follows.」
The Company has restated the potential dilution exposure relating to the Series 10 stock acquisition rights representing 83,000 shares and the Series 11 stock acquisition rights for employees representing 162,400 shares, as resolved on 22 May 2024. - FY2024WorsenedAnnual report
「Resolution date 22 May 2024 Eligible recipients and number of people The Company's directors: 4 Officers and employees of the Company's group: 20 Class, description and number of shares underlying the stock acquisition rights* Common shares: 83,000」
In addition to the 286,100 shares represented by existing Series 9 stock acquisition rights, the Company resolved to issue Series 10 stock acquisition rights representing 83,000 shares and Series 11 stock acquisition rights for employees representing 162,400 shares, expanding potential dilution exposure. - FY2022MitigatedAnnual report
「The decrease in Series 9 stock acquisition rights was due to the exercise of stock acquisition rights.」
Of the stock acquisition rights representing 330,000 shares issued, rights representing 43,900 shares were exercised, leaving 286,100 potential shares at the end of the fiscal year. Potential dilution exposure remains, although it has declined from the time of issuance. - FY2022-Q3WorsenedAnnual report
「Stock acquisition rights issued under the Companies Act during the third quarter accounting period were as follows. Resolution date: 26 November 2021 / Eligible recipients and number of people: the Company's directors, 1 / Number of stock acquisition rights: 3,300 / Class, description and number of shares underlying the stock acquisition rights: common shares, 330,000」
After no stock acquisition rights remained at the end of the previous fiscal year, new stock acquisition rights representing 330,000 common shares were issued, creating potential dilution exposure again. - FY2019MitigatedAnnual report
「The decrease in Series 7 stock acquisition rights during the consolidated fiscal year was due to the exercise of stock acquisition rights.」
All 22,500 underlying shares represented by stock acquisition rights outstanding at the end of the previous fiscal year were exercised, leaving no stock acquisition rights outstanding at the end of the current fiscal year. - FY2018MitigatedAnnual report
「The decrease in stock acquisition rights during the consolidated fiscal year was due to the exercise of stock acquisition rights.」
Stock acquisition rights representing 235,700 shares were exercised, leaving 22,500 underlying shares represented by stock acquisition rights at year-end. The remaining potential shares decreased from 258,200 at the end of the previous fiscal year. - FY2017First statedAnnual report
「As of the end of the consolidated fiscal year, the total number of potential shares represented by stock acquisition rights was 258,200. If all of these rights were exercised, they would represent 6.4% of the total number of shares issued.」
The Company has disclosed the risk of potential dilution equivalent to 6.4% of the total number of shares issued if all stock acquisition rights are exercised.